With multiple FDA drug approvals and a new insulin device, Beximco pharmaceuticals continues to make an impact on the lives of Bangladeshi people

Beximco Pharmaceuticals, a subsidiary of Salman F Rahman’s Beximco Group, continues to ride the high tide of administrative approvals and exports with its recent launch of GENSULIN, a high quality, clinically approved European insulin, and GensuPen2, the first automated and efficient insulin device, in Bangladesh/ .

More than 600 healthcare professionals marked their presence in the launch event. The audience was addressed by a number of prominent personalities including two international physicians: Professor Leszek Czupryniak, Head of Department of Diabetology and Internal Medicine at Warsaw Medical University and Dr Melanie Basio Duran, MD-Diabetologist, The New Beato-Caulin Hospital.

The efforts of Beximco Pharmaceuticals for improving the health condition of Bangladesh can be traced back to its inception in 1980. Serving the country with new, improved, and economical pharmaceuticals, the company, founded by Salman F Rahman and his brother, has played a key role in bolstering the local pharma industry and simultaneously made Bangladesh a leader in the global pharmaceutical market.

This can be corroborated by the fact that Beximco Pharmaceuticals became the first Bangladeshi pharmaceutical company to export medicine to the US market and currently, has a presence in more than 50 countries. Under the leadership of Salman F Rahman, Vice-Chairman of Beximco Group, the company has been successful in striking the difficult balance between product quality and advanced machinery that fuels the research and development efforts. With seven products currently in the US market and operations spanning over approximately four decades, the company could be considered as a pioneer in improving the lives of Bangladeshi citizens.

The event proceeded with a US FDA nod for Cyproheptadine. Addressed by Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals,he stated, “Cyproheptadine is our seventh product approved for the US market, and with our recent acquisition of eight ANDAs from Sandoz, our USA portfolio now stands at 15 products. This approval further increases our confidence that our strategic focus and growing pipeline will strengthen our presence in the world’s largest pharma market.”

Provided that Beximco Pharmaceuticals continues to maintain its current pace, the company will not only increase its contributions in the country’s GDP, but further improve the standard of living of Bangladeshi nationals.